ZR8.F ONCODES.PREC.MED. EO-34

Healthcare Biotechnology Frankfurt Exchange
0.2426 EUR
Close of Nov 12, 2026
0.1800 0.7560
Market cap
EUR 4.63M
P/E
-
P/B
1.13x
ROE
10.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ZR8.F undervalued?

Graham number

The Graham number of ONCODES.PREC.MED. EO-34 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ONCODES.PREC.MED. EO-34 fundamental analysis

No fundamental analysis for ONCODES.PREC.MED. EO-34 yet.

ONCODES.PREC.MED. EO-34 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ONCODES.PREC.MED. EO-34

Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company's product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson's disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced…

Full company profile